All In Biotech

Drug Trial Radar · NCT06823609

Phase I Clinical Study of QLS-1304 in the Treatment of Patients With Advanced Malignant Tumors

A Phase I Clinical Study to Evaluate Safety, Tolerability, PK Characteristic and Preliminary Efficacy of QLS-1304 in Patients With Advanced Malignant Tumors

Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Mar 6, 2025

Primary completion

Nov 2026

Study completion Dec 2027

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Feb 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multi-center, open label, dose escalation/dose expansion phase I clinical trial aimed at evaluating the safety, tolerability, PK characteristics, and preliminary efficacy characteristics of QLS1304 monotherapy in patients with advanced malignant solid tumors. This study was divided into two stages: dose escalation and dose expansion.

Conditions

  • Advanced Malignant Tumor

Interventions

  • QLS1304 tabletDrug

    QLS1304 monotherapy dose escalation and expansion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limited toxicity (DLT) of QLS1304Time frame: up to 35 days
  2. Maximum tolerated dose(MTD)of QLS1304Time frame: up to 35 days
  3. Recommended Phase II Dose (RP2D) of QLS1304Time frame: up to 35 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Cancer Hospital

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.